阿尔茨海默病（Alzheimer’s disease，AD）的核心症状是认知功能损害，并且在不同的病期50％-90％的患者会出现精神和行为症状，是造成痴呆患者家庭经济负担和家属负性心理的重要因素，同时对社会和患者本人都极可能带来危害，也是痴...阿尔茨海默病（Alzheimer’s disease，AD）的核心症状是认知功能损害，并且在不同的病期50％-90％的患者会出现精神和行为症状，是造成痴呆患者家庭经济负担和家属负性心理的重要因素，同时对社会和患者本人都极可能带来危害，也是痴呆患者住院治疗的主要原因。目前国内对痴呆行为和心理症状（behavioral and psychological symptoms of dementia，BPSD）的治疗主要是抗精神病药物，展开更多
Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc-ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in st...Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc-ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in stable MCI. We report that their combined evaluation increases the discriminative power of the analysis in identifying presymptomatic AD. The positive predictive value of these combined markers in identifying progressive MCI was 0.87, and the negative predictive value was 0.90. This observation suggests that the interplay of different markers should be considered for enhancing diagnostic accuracy of pre-clinical AD.展开更多
文摘阿尔茨海默病（Alzheimer’s disease，AD）的核心症状是认知功能损害，并且在不同的病期50％-90％的患者会出现精神和行为症状，是造成痴呆患者家庭经济负担和家属负性心理的重要因素，同时对社会和患者本人都极可能带来危害，也是痴呆患者住院治疗的主要原因。目前国内对痴呆行为和心理症状（behavioral and psychological symptoms of dementia，BPSD）的治疗主要是抗精神病药物，
文摘主观认知下降(subjective cognitive decline,SCD)是指患者主观感受自身较正常状态有认知下降,但常规神经心理客观测试在正常范围的状态。目前认为具有临床前阿尔茨海默病(Alzheimer disease,AD)特点的SCD是AD发展的最初阶段,随病程进展逐渐发展为轻度认知障碍(mild cognitive impairment,MCI)甚至AD[1]。2011年美国国立老化研究所和阿尔茨海默病协会(National Institute on Aging-Alzheimer′s Association,NIA-AA)重新定义了AD不同阶段的诊断标准,明确提出了“临床前AD”的概念及用于研究的标准。根据神经元损伤标志物及轻微认知改变的证据,临床前AD可分为三个阶段[2],其中第三阶段出现认知下降但未达到MCI的标准,即为具有临床前AD特点的SCD。本文就该阶段流行病学、生物标记物、神经心理学进行综述,拟为早期识别AD高危人群并在适合的窗口期采取有效的干预措施提供依据。
文摘Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc-ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in stable MCI. We report that their combined evaluation increases the discriminative power of the analysis in identifying presymptomatic AD. The positive predictive value of these combined markers in identifying progressive MCI was 0.87, and the negative predictive value was 0.90. This observation suggests that the interplay of different markers should be considered for enhancing diagnostic accuracy of pre-clinical AD.
